JP#WUXI RC2708B

WuXi Biologics Signs Innovative Tri-Specific TCE Development Agreement with Vertex Pharmaceuticals

WuXi Biologics Signs License and Research Agreement for Tri-specific T-cell Engager with Vertex Pharmaceuticals

WuXi Biologics and Sunovian Announce Strategic Collaboration on SND006 Process Development and Manufacturing

Morgan Stanley Reduced Stake in Wuxi Biologics (Cayman)

CLSA Report: Wuxi Biologics Outperforms Peers

WuXi Biologics and WuXi ChemPartner to Acquire at Least 60% of Tonox

CICC Maintains Buy Rating on Wuxi Biologics (Cayman)

Multiple HK-listed Companies Announce Major Updates

Major Wuxi Biologics Shareholder Sells Existing Shares

Wu Xiaosheng, CEO of WuXi Biologics, Speaks at JPM Healthcare Conference

Citi Group Launches Voluntary Cash Offer to Acquire eXiao Technology Cayman

WuXi Biologics and Zai Lab Sign TCE Research Collaboration Agreement

Morgan Stanley Maintains Wuxi Biologics 'Neutral' Rating, Raises Target Price

Daiwa Raises Target Price for Wuxi Biologics to HKD 42

WuXi Biologics' Wuxi Factories Obtain GMP Certification and Provide Ophthalmic Biologic Production

WuXi Biologics Briefs on 2026 Business Growth Prospects at Annual Healthcare Conference

WuXi Biologics Launches Global CRDMO Platform

WuXi Biologics to Highlight 2025 Operational and Financial Performance at JPM Healthcare Conference

BlackRock Increases Stake in Wuxi Biologics

WuXi Biologics Obtains ISO 20400 Sustainable Procurement Certification

UNI PRINTSHOP

WING CHI HLDGS

CINESE INTL

WAN KEI GROUP

CHINA WACAN

JH EDUCATION

DIGITAL DOMAIN

LOTUS HORIZON

VICO INTL HLDGS

K W NELSON GP

02269

JP Morgan listed the companies affected by the appreciation of the RMB on the earnings of Chinese stocks, indicating that a 5% appreciation of the RMB against the USD will negatively impact the net profits of several companies. The affected companies include SHENZHOU INTL, Super Ocean International, SMIC, USISH, COWELL, Longi Green Energy, SINOCERA MATERIAL, Zhejiang Dingli, Sany, XCMG, WUXI BIO, WUXI XDC, Jereh Holdings, and Sinopec Oilfield Service, with an expected impact range of 7% to 15%

AASTOCKS

SMIC

A BOS RMB MM-R

SHENZHOU INTL

Sany

A BOS RMB MM

WUXI XDC

SINOCERA MATERIAL

A VP RMB MM

WUXI BIO

USISH

COWELL

XCMG

JP Morgan lists the Chinese stocks that are most negatively impacted by the appreciation of the RMB (Table)

01093

01801

08189

01177

08037

02509

The Hang Seng Biotechnology Index rose over 4% intraday, CSPC PHARMA rose over 7%, INNOVENT BIO rose nearly 7%, WUXI BIO and SINO BIOPHARM rose over 5%

Wallstreetcn

CSPC PHARMA

INNOVENT BIO

TEDA BIOMEDICAL

SINO BIOPHARM

CH BIOTECH SER

QYUNS-B

WXXWY

WuXi Biologics (Cayman) Inc. has been awarded the EcoVadis Platinum Medal for the third consecutive year, ranking in the top 1% of over 150,000 companies assessed globally. The company’s sustainability efforts include approved greenhouse gas emissions reduction targets and a Green CRDMO White Paper on green technologies. WuXi Biologics has also received recognition for its ESG performance, including an MSCI AAA Rating and inclusion in the FTSE4Good Index Series.

Reuters

VG Health

Invesco Nasdaq Biotechnology ETF

Ark Genomic Revolution ETF

SPDR S&P Biotech

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

VanEck Biotech ETF

WuXi Biologics

Proshares Ultra Nasdaq Biotech

iShares US Pharma

Health Care Select Sector SPDR

iShares Global Healthcare

WuXi Biologics Receives EcoVadis Platinum Medal for Third Consecutive Year

589720

588860

588250

512290

513700

Innovent Biologics Inc. reported a 45% year-over-year growth in product revenue for 2025, totaling approximately RMB11.9 billion. In Q4 2025, product revenue reached around RMB3.3 billion, also showing significant growth. The company recognized inventory price adjustments due to the addition of six new drugs to the 2026 National Reimbursement Drug List. This financial information is based on internal records and has not been audited. The original content was published via the Hong Kong Stock Exchange.

Guotai SSE STAR Brand Name Drug ETF

ICBCCS SSE STAR Biology and Medicine ETF

Penghua SSE STAR Biology and Medicine ETF

Guotai CSI Bio-medicine ETF

Penghua CSI HK Connect Health Care Composite ETF

Innovent Biologics Reports 45% Year-Over-Year Growth in 2025 Product Revenue

VRTX

WuXi Biologics and Vertex Pharma signed a licensing and research service agreement regarding the innovative trispecific T cell engagers (TCE). Vertex Pharma will obtain the global exclusive development and commercialization rights for the TCE, while WuXi Biologics will receive an upfront payment as well as subsequent milestone payments and sales royalties, and will provide integrated contract research and development services

Vertex Pharma

WuXi Biologics and Vertex Pharma have reached a licensing and research service agreement for innovative tri-specific TCE

WuXi Biologics has signed a license and research service agreement with Vertex Pharmaceuticals for a trispecific T-cell Engager aimed at treating B-cell mediated autoimmune diseases. Vertex gains exclusive global rights for development and commercialization, while WuXi will receive upfront and milestone payments, along with royalties. This collaboration highlights WuXi's leadership in discovery service solutions and commitment to advancing transformative therapies.

StockTitan

WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager | VRTX Stock News

00HSI

0HSCI

00001

Hong Kong stocks rose 111 points (0.4%) to 26,887, ending a two-day decline. The increase followed positive momentum from Wall Street and eased pressure from last week's selloff in metals and cryptocurrencies. Mainland shares also gained, supported by a private survey indicating factory activity growth. However, caution prevailed ahead of Hong Kong's retail sales data and China's VAT increase on telecom services. All sectors saw gains, particularly property and financials, with notable increases in mining stocks and companies like CK Hutchison and Wuxi Biologics.

Trading Economics

Hang Seng Index

Hang Seng Composite Index

CKH HOLDINGS

Hong Kong Stocks Snap Two-Day Slide

300450

44048

Wuxi Lead Intelligent Equipment to raise up to $549 million in Hong Kong share sale

marketscreener

LEAD INTELLIGENT

WUXI BIO POFF-D

Wuxi Lead Intelligent Equipment to raise up to $549 million in Hong Kong share sale

On January 28, 2026, in Shanghai, WuXi Biologics (stock symbol:, a prominent international Contract Research, Development, and Manufacturing Organization (CRDMO), partnered with Sinorda Biomedicine to collaboratively work on SND006, a groundbreaking drug. This strategic alliance aims to combine resources for the development and production of SND006, marking a significant step in the pharmaceutical industry.

Unusual Whales

E Fund CSI Biotechnology Theme ETF

Bosera Hang Seng Health Care ETF(QDII)

ChinaAMC SSE Health Care ETF Initiating Fund

E Fund Hang Seng SCHK Innovative Drug ETF

China Merchants CSI Biotechnology Theme ETF

E Fund CSI 300 Health Care ETF

Minsheng Royal CSI Biotechnology Theme ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Tianhong CNI BIOMEDICINE ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

ChinaAMC CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Huaan Hang Seng Biotech ETF

China Southern Hang Seng Biotech ETF(QDII)

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Yinhua CSI Innovative Drugs Industry ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

WuXi Biologicsand Sinorda Biomedicine partner to develop SND006, a bispecific antibody.

WuXi Biologics has partnered with Sinorda Biomedicine to develop SND006, a bispecific antibody for autoimmune diseases. The collaboration will leverage WuXi's manufacturing expertise to expedite preclinical studies and the IND application process in China and the U.S. This partnership aims to address unmet medical needs in autoimmune diseases and may extend to other projects in Sinorda's pipeline.

WuXi Biologics and Sinorda Biomedicine Partner to Advance Bispecific Antibody for Autoimmune Diseases

The Hang Seng Index opened higher, refreshing its nearly four-year high; Tencent's performance exceeded expectations, receiving collective bullish calls from major banks; Chip stocks strengthened on the logic of domestic substitution, with SMIC leading the gains; Ping An's stake increase in China Taiping H-shares ignited the insurance sector; Cryptocurrency concept stocks surged as Bitcoin hit a new high; In the pharmaceutical sector, Jingtai Holdings reported its first profit, rising over 11%, while East Buy saw a sudden 12% increase.

Tencent

TENCENT

TENCENT-R

Tencent HK SDR 10to1

Tencent Holdings Limited

Ping An Insurance

PING AN

PING AN-R

Ping An Ins HK SDR2to1

Ping An

SMIC HK SDR 5to1

CPIC

CHINA TAIPING

SUNSHINE INS

Life and Health Insurance

REMEGEN

RemeGen

BEONE MEDICINES

BeOne Medicines

Beigene

FI2 CSOP HSI

HUA HONG SEMI

Hua Hong

INNOCARE

InnoCare Pharma

GRANDSHORES

AKESO

HORIZONROBOT-W

ZA ONLINE

SINOHOPE TECH

GUOTAI JUNAN I

XTALPI

Life Sciences Tools and Services

XL2CSOPHSTECH

Semiconductors

FL2 CSOP HSI

LINEKONG

OKG TECH

Interactive Media and Services

CSOP HS TECH

XI2CSOPHSTECH

EAST BUY

Hot Trades in Hong Kong Stocks (8.14) | Hang Seng Index Hits Four-Year High at Opening, Morgan Stanley Says Foreign Capital Accelerated Inflows into Chinese Stock Market in July

Hong Kong stocks' innovative medicine sector surges 66%, three-pronged approach ignites the golden track

WUXI APPTEC

WuXi AppTec

3SBIO

DUALITYBIO-B

HENGRUI PHARMA

Hengrui Pharma

JOINN

Hong Kong stocks' innovative drugs surge 66%! Three major catalysts ignite the 'golden track', can we still get on board in the second half of the year?

On July 11, the three major stock indices in Hong Kong rose together. In terms of sectors, technology stocks rose collectively, and securities and brokerage stocks mostly increased.

LAOPU GOLD

POP MART

MIXUE GROUP

GUMING

AIA Group

LIANLIAN

OSL GROUP

PICC P&C

The Hang Seng Index is approaching its highest level in nearly 3 years, with Chinese brokerage, insurance, and stablecoin concept stocks remaining hot!

JP#WUXI RC2708B(55247.HK)